Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies

被引：37

作者：

Burt, Richard ^{[1
]}

Warcel, Dana ^{[2
]}

Fielding, Adele K. ^{[1
]}

机构：

[1] UCL Canc Inst, 72 Huntley St, London WC1E 6DD, England

[2] UCLH, London, England

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2019年 / 15卷 / 03期

关键词：

blinatumomab; acute lymphoblastic Leukaemia; B-cell non hodgkin Lymphoma; immunotherapeutics; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; RELAPSE-FREE SURVIVAL; NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; INOTUZUMAB OZOGAMICIN; ADULT PATIENTS; ELDERLY-PATIENTS; SINGLE-ARM; PHASE-II;

D O I：

10.1080/21645515.2018.1540828

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient's T cells with CD19-expressing tumour cells. Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-Hodgkin's Lymphoma including in patients who are refractory to chemotherapy. This review summarises the development and design of Blinatumomab, the outcome of clinical studies demonstrating its efficacy and how to manage the administration, practically, including relevant toxicities. We compare and contrast it to other emerging agents for treatment of B-cell malignancies.

引用

页码：594 / 602

页数：9

共 58 条

[51] A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy [J].

Trneny, Marek ;

Verhoef, Gregor ;

Dyer, Martin J. S. ;

Ben Yehuda, Dina ;

Patti, Caterina ;

Canales, Miguel ;

Lopez, Andres ;

Awan, Farrukh T. ;

Montgomery, Paul G. ;

Janikova, Andrea ;

Barbui, Anna M. ;

Sulek, Kazimierz ;

Terol, Maria J. ;

Radford, John ;

Guidetti, Anna ;

Nicola, Massimo D. I. ;

Siraudin, Laure ;

Hatteville, Laurence ;

Schwab, Sandrine ;

Oprea, Corina ;

Gianni, Alessandro M. .

HAEMATOLOGICA, 2018, 103 (08) :1351-1358

[52] Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia [J].

Uy, Natalie ;

Nadeau, Michelle ;

Stahl, Maximilian ;

Zeidan, Amer M. .

JOURNAL OF BLOOD MEDICINE, 2018, 9 :67-74

[53]

Viardot A, 2016, BLOOD, V127, P1410, DOI [10.1182/blood-2015-06651380, 10.1182/blood-2015-06-651380]

[54] Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia [J].

von Stackelberg, Arend ;

Locatelli, Franco ;

Zugmaier, Gerhard ;

Handgretinger, Rupert ;

Trippett, Tanya M. ;

Rizzari, Carmelo ;

Bader, Peter ;

O'Brien, Maureen M. ;

Brethon, Benoit ;

Bhojwani, Deepa ;

Schlegel, Paul Gerhardt ;

Borkhardt, Arndt ;

Rheingold, Susan R. ;

Cooper, Todd Michael ;

Zwaan, Christian M. ;

Barnette, Phillip ;

Messina, Chiara ;

Michel, Gerard ;

DuBois, Steven G. ;

Hu, Kuolung ;

Zhu, Min ;

Whitlock, James A. ;

Gore, Lia .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) :4381-+

[55] Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial [J].

Vora, Ajay ;

Goulden, Nick ;

Mitchell, Chris ;

Hancock, Jeremy ;

Hough, Rachael ;

Rowntree, Clare ;

Moorman, Anthony V. ;

Wade, Rachel .

LANCET ONCOLOGY, 2014, 15 (08) :809-818

[56] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma [J].

Wang, Michael L. ;

Rule, Simon ;

Martin, Peter ;

Goy, Andre ;

Auer, Rebecca ;

Kahl, Brad S. ;

Jurczak, Wojciech ;

Advani, Ranjana H. ;

Romaguera, Jorge E. ;

Williams, Michael E. ;

Barrientos, Jacqueline C. ;

Chmielowska, Ewa ;

Radford, John ;

Stilgenbauer, Stephan ;

Dreyling, Martin ;

Jedrzejczak, Wieslaw Wiktor ;

Johnson, Peter ;

Spurgeon, Stephen E. ;

Li, Lei ;

Zhang, Liang ;

Newberry, Kate ;

Ou, Zhishuo ;

Cheng, Nancy ;

Fang, Bingliang ;

McGreivy, Jesse ;

Clow, Fong ;

Buggy, Joseph J. ;

Chang, Betty Y. ;

Beaupre, Darrin M. ;

Kunkel, Lori A. ;

Blum, Kristie A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06) :507-516

[57] Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy [J].

Wilson, WH ;

Grossbard, ML ;

Pittaluga, S ;

Cole, D ;

Pearson, D ;

Drbohlav, N ;

Steinberg, SM ;

Little, RF ;

Janik, J ;

Gutierrez, M ;

Raffeld, M ;

Staudt, L ;

Cheson, BD ;

Longo, DL ;

Harris, N ;

Jaffe, ES ;

Chabner, BA ;

Wittes, R ;

Balis, F .

BLOOD, 2002, 99 (08) :2685-2693

[58] Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment [J].

Zugmaier, Gerhard ;

Goekbuget, Nicola ;

Klinger, Matthias ;

Viardot, Andreas ;

Stelljes, Matthias ;

Neumann, Svenja ;

Horst, Heinz-A. ;

Marks, Reinhard ;

Faul, Christoph ;

Diedrich, Helmut ;

Reichle, Albrecht ;

Brueggemann, Monika ;

Holland, Chris ;

Schmidt, Margit ;

Einsele, Hermann ;

Bargou, Ralf C. ;

Topp, Max S. .

BLOOD, 2015, 126 (24) :2578-2584

← 1 2 3 4 5 6 →